ZLZongyi Liu

Zongyi Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zongyi Liu has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Hang Chen

    Institute of Hepatopancreatobiliary Surgery, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University, Chongqing 401147, China

    1 shared publication
  • Hongyan Xiang

    Department of Geriatrics, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University, No. 118, Xingguang Avenue, Liangjiang New Area, Chongqing 401147, China

    1 shared publication
  • Huanyu Xiang

    Department of Geriatrics, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University, No. 118, Xingguang Avenue, Liangjiang New Area, Chongqing 401147, China

    1 shared publication
  • Jie Zhang

    Department of Geriatrics, Chongqing Academy of Medical Sciences, Chongqing General Hospital, Chongqing University, No. 118, Xingguang Avenue, Liangjiang New Area, Chongqing 401147, China

    1 shared publication
  • Shuliang Guo

    Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

    1 shared publication
  • Zhidan Luo

    Department of Geriatric Medicine, Chongqing Clinical Research Center for Geriatric Diseases, Chongqing General Hospital, Chongqing University, Chongqing, China

    1 shared publication

Latest Publications

  • Open Access

    Gut Commensal Bacteria Ameliorate Liver Fibrosis by Inhibiting Macrophage M1 Polarization Through Secondary Bile Acids in a Murine Liver Fibrosis Model

    by Hongyan Xiang, Huanyu Xiang, Zongyi Liu, Hang Chen, Zhidan Luo, Shuliang Guo, Jie Zhang

    The gut microbiota plays a critical role in regulating liver metabolism and immunity, significantly influencing hepatic inflammation and fibrogenesis. However, the mechanisms by which it modulates the progression of liver fibrosis remain unclear. This study investigated the interplay between the gut microbiota and bile acids in murine liver fibrosis. A mouse model of liver fibrosis was established via intraperitoneal injection of carbon tetrachloride. The gut microbiota was depleted using an antibiotic cocktail, as confirmed through 16S rRNA sequencing. Bile acid profiles were measured using ultra-performance liquid chromatography–tandem mass spectrometry. The effects of secondary bile acids on macrophage polarization were assessed in vivo and in vitro. Gut commensal microbiota depletion exacerbated liver inflammation and fibrosis. Concomitantly, this depletion significantly reduced microbiota-derived secondary bile acids. Notably, supplementation with deoxycholic acid markedly attenuated liver fibrosis. This protective effect was associated with the inhibition of pro-inflammatory M1 macrophage polarization. Takeda G protein-coupled receptor 5 (TGR5) activation was identified as the mechanism underlying the effect of deoxycholic acid on macrophages, as a TGR5 antagonist reversed this inhibition. Mechanistically, TGR5 activation suppressed the NF-κB pathway in macrophages via the cAMP–PKA signaling cascade, thereby inhibiting hepatic stellate cell activation. Our results demonstrate that the gut microbiota–secondary bile acid–TGR5 signaling axis plays a critical role in liver fibrosis and represents a promising therapeutic target.